Impact of tissue-agnostic approvals on management of primary brain tumors
Copyright © 2023 Elsevier Inc. All rights reserved..
Novel tissue-agnostic therapeutics targeting driver mutations in tumor cells have been recently approved by FDA, driven by basket trials that have demonstrated their efficacy and safety across diverse tumor histology. However, the relative rarity of primary brain tumors (PBTs) has limited their representation in early trials of tissue-agnostic medications. Thus, consensus continues to evolve regarding utility of tissue-agnostic medications in routine practice for PBTs, a diverse group of neoplasms characterized by limited treatment options and unfavorable prognoses. We describe current and potential impact of tissue-agnostic approvals on management of PBTs. We discuss data from clinical trials for PBTs regarding tissue-agnostic targets, including BRAFV600E, neurotrophic tyrosine receptor kinase (NTRK) fusions, microsatellite instability-high (MSI-High), mismatch repair deficiency (dMMR), and high tumor mutational burden (TMB-H), in context of challenges in managing PBTs. Described are additional tissue-agnostic targets that hold promise for benefiting patients with PBTs, including RET fusion, fibroblast growth factor receptor (FGFR), ERBB2/HER2, and KRASG12C, and TP53Y220C.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Trends in cancer - 10(2024), 3 vom: 15. März, Seite 256-274 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ahluwalia, Manmeet S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BRAFV600E |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.trecan.2023.11.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367358689 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367358689 | ||
| 003 | DE-627 | ||
| 005 | 20240315233123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240121s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.trecan.2023.11.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM367358689 | ||
| 035 | |a (NLM)38245379 | ||
| 035 | |a (PII)S2405-8033(23)00236-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ahluwalia, Manmeet S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of tissue-agnostic approvals on management of primary brain tumors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Novel tissue-agnostic therapeutics targeting driver mutations in tumor cells have been recently approved by FDA, driven by basket trials that have demonstrated their efficacy and safety across diverse tumor histology. However, the relative rarity of primary brain tumors (PBTs) has limited their representation in early trials of tissue-agnostic medications. Thus, consensus continues to evolve regarding utility of tissue-agnostic medications in routine practice for PBTs, a diverse group of neoplasms characterized by limited treatment options and unfavorable prognoses. We describe current and potential impact of tissue-agnostic approvals on management of PBTs. We discuss data from clinical trials for PBTs regarding tissue-agnostic targets, including BRAFV600E, neurotrophic tyrosine receptor kinase (NTRK) fusions, microsatellite instability-high (MSI-High), mismatch repair deficiency (dMMR), and high tumor mutational burden (TMB-H), in context of challenges in managing PBTs. Described are additional tissue-agnostic targets that hold promise for benefiting patients with PBTs, including RET fusion, fibroblast growth factor receptor (FGFR), ERBB2/HER2, and KRASG12C, and TP53Y220C | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a BRAFV600E | |
| 650 | 4 | |a KRAS | |
| 650 | 4 | |a RET fusion | |
| 650 | 4 | |a brain tumors | |
| 650 | 4 | |a genomic medicine | |
| 650 | 4 | |a microsatellite instability | |
| 650 | 4 | |a mismatch repair | |
| 650 | 4 | |a neurotrophic tyrosine receptor kinase | |
| 650 | 4 | |a precision medicine | |
| 700 | 1 | |a Khosla, Atulya A |e verfasserin |4 aut | |
| 700 | 1 | |a Ozair, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Gouda, Mohamed A |e verfasserin |4 aut | |
| 700 | 1 | |a Subbiah, Vivek |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trends in cancer |d 2015 |g 10(2024), 3 vom: 15. März, Seite 256-274 |w (DE-627)NLM253590183 |x 2405-8025 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g number:3 |g day:15 |g month:03 |g pages:256-274 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.trecan.2023.11.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |e 3 |b 15 |c 03 |h 256-274 | ||